National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Dr. Falk Pharma GmbH engages in the development and sale of medication for indications in hematology and gastroenterology in Germany and internationally. The company principally offers prescription drugs that are used in treating inflammatory bowel diseases, cholestatic liver diseases, irritable bowel syndromes, and constipation, as well as for colon cleansing prior to colonoscopies. It also organizes and sponsors medical education events; and offers publications for healthcare professionals, as well as for patients and their families. The company was formerly known as Dr. Falk Arzneimittel GmbH & Co KG and changed its name to Dr. Falk Pharma GmbH in 1989. Dr. Falk Pharma GmbH was founded in 1960 and is headquartered in Freiburg, Germany

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Concateno UK Ltd. provides drug, alcohol and healthcare testing services. The company is headquartered in Abingdon, the United Kingdom.

Nanjing Norman Biological Technology Co., Ltd is dedicated to R&D and manufacturing of automated chemiluminescence system. Founded in 2008, Norman biological has been upholding the idea that R&D shapes future ,and concentration determines success. Ever since the beginning, Norman has been focusing on developing and manufacturing chemiluminescence instruments and reagents. Norman’s manufacture center is located in the Yuhua District and owns an over 2,000m2 GMP-approved clean workshop. The R&D base, which is over 2,000m2 , is located in state-level new Jiangbei district. Now there are over 100 R&D engineers, 40% of which hold a PhD or master’s degree.

Shenzhen Zeqingyuan Technology Development Service Co., Ltd., established on 2014-01-10, Business scope includes general business items:technology incubation,Evaluation of scientific and technological achievements,transfer,Transaction and Assurance Services;R & D,Transfer, transformation and application of scientific and technological achievements;data mining,Data Analysis and Data Services;3CProduct design development and sales;software development;Enterprise Asset Management,Intellectual property agency;Supply Chain Management Services;Development and application of modern logistics technology and logistics information system;Industry Information Consulting and Services,Domestic Trade(Does not contain franchise,Exclusive control,Monopoly);New material research and development and sales;Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).grain sales;Bean and potato sales;Wholesale Fresh Vegetables;gift flower sale;Fresh Fruit Wholesale;Fresh Fruit Retail;real estate herbal medicine(Does not contain Chinese herbal medicine)buy and sell;Comprehensive utilization of agricultural, forestry, animal husbandry and fishery waste;Eco-environmental material sales;Research and development of bio-based materials technology;Sales of bio-based materials;Intelligent Agricultural Management;Sales of agricultural and sideline products;Wholesale of edible agricultural products;Fresh Meat Wholesale.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:

Jiangsu Haitel Machinery Co., Ltd., established on 2007-11-09, Business scope includes food machinery,Pharmaceutical machinery,Packaging Machinery,textile machinery,Agricultural machinery research and development,manufacture,Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Provides research and development on medical sciences and pharmacy

Korea Food Research Institute is a global food R&D institution that contributes to the health of Korea.

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment businesses; Connected Care businesses; Personal Health businesses; and Other. The Diagnosis and Treatment businesses segment consists systems, smart devices, software and services, powered by AI-enabled informatics-that support precision diagnoses and minimally invasive procedures in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care businesses segment consists Hospital Patient Monitoring, Emergency Care, Sleep & Respiratory Care and Connected Care Informatics. The Personal Health businesses segment consists of Oral Healthcare, Personal Care,Mother and Child Care. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Unipath Ltd., part of Abbott Laboratories, is a company headquartered in Bedford, UK. The firm manufactures female healthcare products. It was founded in 1946 by Paul James Davis. Alere, Inc. acquired Unipath Ltd. from Unilever NV on December 20, 2001 for $146.54 million.

American Bio Medica Corp. is a biotechnology company, which engages in the manufacture and sale of immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids. The firm's products include Rapid Drug Screen, Rapid ONE, RDS InCup, Rapid TOX, Rapid TOX Cup II, and OralStat. Its products are related to urinalysis, oral fluids, alcohol testing, hair testing, pregnancy testing, and lab partners. The company was founded by Stan Cipkowski and Edmund M. Jaskiewicz on April 2, 1986 and is headquartered in Kinderhook, NY.

Kumho Petrochemical is a manufacturer of synthetic resins, fine chemicals, energy, building materials and other plastic materials.

Engages in the development and commercialization of diagnostic products

CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.